Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the granting of non-statutory stock options to two new employees. These grants were made under the company's 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The new employees received an aggregate of 90,000 options to purchase Fulcrum's common stock at an exercise price of $3.57 per share, which was the closing price on the grant effective date, October 7, 2024. Each option has a ten-year term and vests over four years, with 25% vesting on the first anniversary of the employee's start date and an additional 6.25% vesting quarterly over the following three years, subject to continued employment.
Fulcrum Therapeutics (Nasdaq: FULC), un'azienda biofarmaceutica in fase clinica, ha annunciato l'assegnazione di opzioni su azioni non statutarie a due nuovi dipendenti. Questi conferimenti sono stati effettuati nell'ambito del Piano di Incentivazione per Opzioni su Azioni per il 2022 della società, in conformità con la Regola 5635(c)(4) della Nasdaq.
I nuovi dipendenti hanno ricevuto un totale di 90.000 opzioni per acquistare azioni comuni di Fulcrum a un prezzo d'esercizio di $3,57 per azione, che corrisponde al prezzo di chiusura della data di efficacia dell'assegnazione, il 7 ottobre 2024. Ogni opzione ha un termine di dieci anni e si matura in quattro anni, con il 25% che matura al primo anniversario della data di assunzione del dipendente e un ulteriore 6,25% che matura trimestralmente nei successivi tre anni, soggetto a continuare l'impiego.
Fulcrum Therapeutics (Nasdaq: FULC), una compañía biofarmacéutica en etapa clínica, ha anunciado la concesión de opciones sobre acciones no estatutarias a dos nuevos empleados. Estas concesiones se realizaron bajo el Plan de Incentivos de Acciones por Inducción 2022 de la compañía, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Los nuevos empleados recibieron un total de 90,000 opciones para comprar acciones comunes de Fulcrum a un precio de ejercicio de $3.57 por acción, que fue el precio de cierre en la fecha efectiva de concesión, el 7 de octubre de 2024. Cada opción tiene un plazo de diez años y se adquiere en un período de cuatro años, con un 25% que se adquiere en el primer aniversario de la fecha de inicio del empleado y un adicional del 6.25% que se adquiere trimestralmente durante los tres años siguientes, sujeto a la continuidad del empleo.
Fulcrum Therapeutics (Nasdaq: FULC)는 임상 단계의 생명공학 회사로, 두 명의 신규 직원에게 비법정 주식매수선택권을 부여한다고 발표했습니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 회사의 2022 유인 주식 인센티브 계획에 따라 이루어졌습니다.
신규 직원들은 총 90,000개의 옵션을 받았으며, Fulcrum의 보통주를 주당 $3.57의 행사 가격으로 구매할 수 있습니다. 이는 부여 효력 발생일인 2024년 10월 7일의 종가입니다. 각 옵션은 10년의 기간을 가지며 4년에 걸쳐 분할 지급됩니다. 고용 시작일의 첫 번째 기념일에 25%가 지급되고, 이후 3년 동안 매 분기마다 추가로 6.25%가 지급되며, 이는 계속해서 고용 상태를 유지해야 합니다.
Fulcrum Therapeutics (Nasdaq: FULC), une entreprise biopharmaceutique en phase clinique, a annoncé l'octroi d'options d'achat d'actions non statutaires à deux nouveaux employés. Ces octrois ont été effectués dans le cadre du Plan d'Incentive d'Actions 2022 de la société, conformément à la Règle d'Inscription 5635(c)(4) de Nasdaq.
Les nouveaux employés ont reçu un total de 90 000 options pour acheter des actions ordinaires de Fulcrum à un prix d'exercice de 3,57 $ par action, qui correspond au prix de clôture à la date de prise d'effet de l'octroi, le 7 octobre 2024. Chaque option a une durée de dix ans et s'acquiert sur quatre ans, avec 25% s'acquérant à la première date d'anniversaire du début d'emploi de l'employé et 6,25% supplémentaires s'acquérant trimestriellement au cours des trois années suivantes, sous réserve de la continuité de l'emploi.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat die Gewährung nicht-statutärer Aktienoptionen an zwei neue Mitarbeiter angekündigt. Diese Gewährungen erfolgten im Rahmen des Aktienoptionsplans 2022 der Gesellschaft, gemäß der Nasdaq-Aufsichtsregel 5635(c)(4).
Die neuen Mitarbeiter erhielten insgesamt 90.000 Optionen zum Kauf von Stammaktien von Fulcrum zu einem Ausübungspreis von 3,57 $ pro Aktie, was dem Schlusskurs am Tag der Wirksamkeit der Zuteilung, dem 7. Oktober 2024, entspricht. Jede Option hat eine Laufzeit von zehn Jahren und wird über vier Jahre fällig, wobei 25% am ersten Jahrestag des Arbeitsbeginns des Mitarbeiters fällig werden und zusätzlich 6,25% vierteljährlich in den folgenden drei Jahren fällig werden, vorausgesetzt, das Arbeitsverhältnis bleibt bestehen.
- Granting stock options may help attract and retain talented employees
- The vesting schedule encourages long-term employee retention
- Potential dilution of existing shareholders' equity due to new stock options
CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum granted the new employees an aggregate of 90,000 options to purchase shares of the company’s common stock at an exercise price of
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
How many stock options did Fulcrum Therapeutics (FULC) grant to new employees?
What is the exercise price of the stock options granted by Fulcrum Therapeutics (FULC)?
What is the vesting schedule for the stock options granted by Fulcrum Therapeutics (FULC)?
Under which plan did Fulcrum Therapeutics (FULC) grant these stock options?
